Mitchell Chan - 02 Jan 2025 Form 4 Insider Report for REGENXBIO Inc. (RGNX)

Role
Chief Financial Officer
Signature
/s/ Patrick J. Christmas as attorney-in-fact
Issuer symbol
RGNX
Transactions as of
02 Jan 2025
Transactions value $
$0
Form type
4
Filing time
06 Jan 2025, 16:59:14 UTC
Previous filing
18 Sep 2024
Next filing
01 Apr 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RGNX Stock Options (Right to buy) Award $0 +62.5K $0.00 62.5K 02 Jan 2025 Common Stock 62.5K $7.86 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 2, 2026 while the optionee provides continuous service to the Issuer.